Treatment Options for High-Risk, Clinically Localized Prostate CancerJuly 20th 2022
Dr Stephen Freedland outlines the currently available, NCCN-recommended treatment options for patients with high-risk, clinically localized prostate cancer, and the clinical challenges he faces during the treatment decision-making process.
For Medicaid-insured patients with cancer, health insurance does not always mean health accessJuly 19th 2022
“We found that Medicaid acceptance differed widely across cancer care facilities," said Michael Leapman, MD, MHS, associate professor of Urology, clinical program leader for the Prostate & Urologic Cancers Program at Yale Cancer Center and Smilow Cancer Hospital.
Available Single-Agent and Combination Therapies for mCSPCJuly 19th 2022
Dr Gordon Brown provides an overview of single-agent androgen deprivation therapy (ADT) and other regimens that may be used in combination with ADT, including androgen receptor (AR) inhibitors, for treatment of mCSPC.
Moffitt study shows adaptive therapy improves outcomes, reduces care costs for prostate cancer patientsJune 30th 2022
“These analyses illustrate the critical role for inclusion of mathematical models, evolutionary first principles and computer simulations in trial design. Unlike conventional clinical trials, this approach allows both cohort and patient-specific analyses," said Jingsong Zhang, MD, PhD.
Treatment intensification for high-risk localized prostate cancer: The time has comeJune 29th 2022
"What we still need to trial is the use of treatment intensification or triple therapy in men with high-risk localized and/or locally advanced disease," writes Michael S. Cookson, MD, MMHC.
Pivotal olaparib/abiraterone mCRPC data published in New England Journal of Medicine EvidenceJune 22nd 2022
The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to frontline abiraterone acetate significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
UCSF prostate cancer specialist inducted into annual class of Giants of Cancer CareJune 21st 2022
Eric J. Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.